Literature DB >> 32489027

[Recent advances in treatment of viral pneumonia using Chinese patent medicine].

Tao Wang1, Li-Feng Han1, Yue-Fei Wang1, Lin Miao1, Jian Yang1, Jun-Hua Zhang1, Xiu-Mei Gao1, Bo-Li Zhang1.   

Abstract

Viral pneumonia is caused by a spreading of lung infection caused by respiratory viruses. Some virus infections were found to be highly aggressive, leading to lung inflammation and severe damage in respiratory system with high fatality rate. Currently, there is no effective therapeutic drugs in the clinic. The common clinical symptoms of viral pneumonias include fever, rhinitis, runny nose, nonproductive cough, fatigue, myalgias and headaches after the immune system being tricked by driving cytokines and overactivated immune response induced by cytokine storms. Patients with severe symptoms could get persistent high fever, dysfunctional breathing, consciousness disorders and even respiratory failure, post-inflammatory pulmonary fibrosis, multi-organ damages, shock and so on. Most clinical treatments are used to inhibit virus replication, relieve symptoms, inhibit excessive inflammatory response, regulate immune balance and protect organs. Both applied and basic research demonstrate that Chinese patent medicine has certain anti-viral effects, effectively inhibiting viral pneumonia transiting from mild to severe, rapid relieving of patient symptoms because of their multi-component and multi-target integrated roles. This review has summarized the reports on the treatment of viral pneumonia. Based on the pathogenic characteristics of viral pneumonia, this paper summarizes the diverse roles of the marketed Chinese patent medicine, such as their effects in inhibiting the progress of viral replication and overactivated inflammatory response, regulating immune balance, attenuating pulmonary fibrosis and so forth. Our paper summarizes the advantages of Chinese patient medicine in the treatment of viral pneumonia, based on which improvements of clinical therapy are expected to be made soon.

Entities:  

Keywords:  2019-nCoV; COVID-19; immunity; inflammation; pulmonary fibrosis; viral pneumonia; viral replication

Year:  2020        PMID: 32489027     DOI: 10.19540/j.cnki.cjcmm.20200312.502

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  2 in total

1.  Traditional Chinese medicine injection for the treatment of viral pneumonia in children: A protocol for systematic review and meta-analysis.

Authors:  Li Fang; Jiaoru Pei; Song Mao; Liangxia Wu; Siqiong Jiang
Journal:  Medicine (Baltimore)       Date:  2021-04-23       Impact factor: 1.817

Review 2.  Chinese medical drugs for coronavirus disease 2019: A systematic review and meta-analysis.

Authors:  Wentai Pang; Zhi Liu; Nan Li; Yuyun Li; Fengwen Yang; Bo Pang; Xinyao Jin; Wenke Zheng; Junhua Zhang
Journal:  Integr Med Res       Date:  2020-07-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.